TCF3::PBX1 (E2A::PBX1) t(1;19)
Quantitative RT-PCR detection of TCF3::PBX1 (E2A::PBX1) fusion from t(1;19) for ALL diagnosis and minimal residual disease monitoring.
KMT2A::MLLT3 (MLL::AF9) t(9;11)
Quantitative RT-PCR detection of KMT2A::MLLT3 fusion transcripts from the t(9;11) translocation.
KMT2A::AFDN t(6;11) (aka KMT2A::MLLT4 or MLL::AF6)
Quantitative RT-PCR detection of KMT2A::AFDN fusion transcripts from t(6;11) involving the 11q23 KMT2A locus.
BCR::ABL1 IS t(9;22)
Quantitative RT-PCR detection and monitoring of the t(9;22) BCR::ABL1 fusion transcript (p210 and p190) for CML, ALL, and AML diagnosis and MRD.
BCR::ABL1 Qualitative Breakpoints p190 vs p210
Qualitative RT-PCR identification of BCR::ABL1 fusion transcript breakpoint type (major p210 vs minor p190) for diagnosis of CML, ALL, and AML.
ABL1 Tyrosine Kinase Domain Mutation Analysis
Sanger sequencing of ABL1 tyrosine kinase domain to detect imatinib resistance mutations in BCR::ABL1-positive CML, ALL, and AML.
KMT2A::MLLT11 (MLL::AF1) t(1;11)
Quantitative RT-PCR detection of KMT2A::MLLT11 fusion transcripts from the t(1;11) translocation.
KMT2A::MLLT1 / KMT2A::ELL t(11;19)
Quantitative RT-PCR detection of KMT2A::MLLT1 (MLL::ENL) and KMT2A::ELL (MLL::ELL) fusion transcripts from t(11;19) in ALL and AML.
KMT2A::MLLT10 (MLL::AF10) t(10;11)
Quantitative RT-PCR detection of KMT2A::MLLT10 fusion transcripts from the t(10;11) translocation.
KMT2A::AFF1 t(4;11) (aka MLL::AF4)
Quantitative RT-PCR detection of KMT2A::AFF1 fusion transcripts from t(4;11), associated with poor prognosis in B-ALL.
